A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is administered after completing trastuzumab treatment.
One of only a few vaccines of its kind in development, GP2 has been shown to be safe and effective for breast cancer patients, reducing recurrence rates by 57%. Further, women with the HER2 positive disease, 3+ score, had no cancer recurrences when they were administered the vaccine after completing trastuzumab, a monoclonal antibody, passive immunotherapy. HER2 is an oncoprotein that promotes tumour growth. Read more here.
No comments:
Post a Comment